All In Biotech

NDA 218764 · Boehringer Ingelheim

Jascayd

Nerandomilast · Oral

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Oct 7, 2025: To treat idiopathic pulmonary fibrosis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Oct 7, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

35

11 Phase 3, 7 recruiting

FAERS reports

1,737

635 serious, 175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 14, 2026.

JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. ( 1.1 ) The treatment of progressive pulmonary fibrosis in adult patients. ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. 1.2 Progressive Pulmonary Fibrosis JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

Mechanism: Nerandomilast is an inhibitor of phosphodiesterase 4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition elevates intracellular cAMP levels and reduces the expression of profibrotic growth factors and inflammatory cytokines, which are overexpressed in IPF and PPF.

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 7, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • JASCAYD · NERANDOMILAST 18MG · TABLET, ORAL · Prescription
  • JASCAYD · NERANDOMILAST 9MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nerandomilast" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea488
  • nausea196
  • fatigue192
  • headache184
  • dyspnoea183
  • cough164
  • dizziness150
  • decreased appetite117
  • death101
  • back pain89
  • weight decreased87
  • pneumonia66

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20232
20241
2025111
20261,623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.